摘要
原发免疫性血小板减少症是一种获得性免疫介导的以血小板减少、伴或不伴皮肤黏膜瘀紫、鼻衄、内脏出血等为特征的自身免疫性疾病。近年来,原发免疫性血小板减少症的治疗进展迅速,尤其是血小板受体激动剂艾曲波帕的出现。本文就原发免疫性血小板减少症的治疗研究进展作一综述。
Primary immune thrombocytopenia is an autoimmune disease characterized by reduced platelets, accompanied by or without skin mucous bruises,epistaxis,intemal bleeding,etc.Recent years,the treatment of primary immune thrombocytopenia developed very quickly,including the appearance of platelet receptor agonist -Eltrom-bopag.Here,we reviewed the treatment and research development of primary immune thrombocytopenia.
作者
毛东锋
毛军峰
吴涛
白海
Mao Dongfeng;Mao Junfeng;Wu Tao;Bai Hai(Department of Hematology,Lanzhou General Hospital of Lanzhou Command ,Lanzhou,Gansu 730050,China;Department of Nuclear Medicine ,PET/CT Center,Lanzhou General Hospital of Lanzhou Command,Lanzhou,Gansu 730050,China)
出处
《中国基层医药》
CAS
2019年第2期253-256,共4页
Chinese Journal of Primary Medicine and Pharmacy
基金
甘肃省自然科学基金资助(145RJZA151).
